Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.
Cancer Res. 2022 Jan 15;82(2):307-319. doi: 10.1158/0008-5472.CAN-21-0732. Epub 2021 Nov 22.
Cancer Res. 2022.
PMID: 34810199
Free PMC article.